VALNEVA SE EO -_15
Commented by Stefan Feulner on November 3rd, 2021 | 10:16 CET
Valneva, Cardiol Therapeutics, BioNTech - Is the vaccination subscription coming?
The numbers of people infected with Corona have been rising significantly again for weeks. While only about 67% of Germans are fully vaccinated, the pace is slowing noticeably. Meanwhile, the third dose, the so-called "booster" vaccination, has already been started. The Standing Commission on Vaccination (STIKO) has recommended this booster for people aged 70 and over. A decision on whether booster vaccinations should be offered to everyone is likely to be made soon. For vaccine manufacturers, this means recurring revenues.
Read
Commented by Fabian Lorenz on November 2nd, 2021 | 12:14 CET
Varta, Valneva, Almonty Industries: It is getting close!
Volkswagen, SMA Solar, Asos are just a few examples; hardly a day goes by without companies from a wide variety of industries complaining about shortages. Be it computer chips for the automotive industry, industrial raw materials for production or transportation options. But there are also winners. Among them is tungsten producer Almonty Industries with its project of the century in South Korea. Germany's Varta is looking to profit from the battery shortage, and excitement is building ahead of the numbers. And Valneva, after its successful capital increase, is hoping that corona vaccines will continue to be in demand.
Read
Commented by Carsten Mainitz on October 12th, 2021 | 12:32 CEST
Defence Therapeutics, BioNTech, Valneva - When will things pick up again?
Biotechnology companies can experience a significant, sometimes even exponential, increase in value virtually overnight with a new, successful active ingredient. BioNTech is a prime example of this. But not every research effort leads to success, and CureVac shareholders can tell you a thing or two about that. Canada's Defence Therapeutics and Valneva have innovative research pipelines. Where should investors consider investing now?
Read
Commented by André Will-Laudien on October 8th, 2021 | 10:25 CEST
BioNTech, Defence Therapeutics, Valneva, Formycon - Close to the bio-revolution!
Portugal is one of the countries with the highest vaccination rate, with 86% of the population already vaccinated. Approximately 98% of those eligible for vaccination - including everyone over the age of 12 - have been vaccinated. Germany, with about 64%, is one of the more vaccine-weary nations. What is the secret of the Portuguese? The government relied on an opinion maker from within its ranks, Admiral Gouveia e Melo. An expert in complicated logistical tasks in the military, he was appointed in February as the top leader of the national vaccination campaign. He is never seen without his military combat uniform in numerous public television appearances - and when asked how other countries can move their own vaccination effort forward, the admiral did not hesitate to offer his best advice: "You have to find people who are not politicians." Where are the current opportunities in the vaccination sector?
Read
Commented by Armin Schulz on October 6th, 2021 | 12:32 CEST
Valneva, Cardiol Therapeutics, BioNTech - New vaccines needed against Corona
Johnson & Johnson's new study shows the booster vaccine improves protection against severe Corona disease by 75%. According to the New York Times, the Company plans to seek approval for the booster vaccine. While the FDA has already approved BioNTech's booster vaccine for those over 65, Moderna and Johnson & Johnson have yet to receive approvals. Those are on the agency's Oct. 14 and 15 meeting schedule. BioNTech CEO Ugur Sahin stressed to the Financial Times that there must always be new formulations to stop new virus variants.
Read
Commented by Carsten Mainitz on September 28th, 2021 | 11:19 CEST
Cardiol Therapeutics, BioNTech, Valneva - Volatility offers good opportunities!
The share prices of the Corona vaccine manufacturers are not growing sky-high after all. Most recently, developments at France's Valneva caused uncertainty. The French Company wanted to bring a Corona vaccine to market by the end of 2021 and had already received an order from the British government for 100 million units. This contract has now been canceled. Where does the industry go from here?
Read
Commented by Armin Schulz on September 27th, 2021 | 13:24 CEST
Valneva, Defence Therapeutics, CureVac - Second-tier vaccine makers offer high potential
The battle against the Coronavirus is still ongoing, although more and more people have been vaccinated with vector or mRNA vaccines. In Europe, an average of 60% of all people have received the vaccination. Herd immunity has not yet been achieved, in part because of vaccine skeptics who do not yet trust novel vaccines. New vaccines based on dead viruses promise to remedy the situation. This method has already been tried and tested in influenza vaccinations, for example. According to a study in Switzerland, about 70% of the unvaccinated would still be vaccinated if the method had already been tested. Herd immunity could thus be achieved, and everyday life could return to normal. So, which vaccine manufacturer that does not currently have an approved product could shake up the market?
Read
Commented by Fabian Lorenz on September 24th, 2021 | 14:10 CEST
BioNTech, Valneva, Defence Therapeutics: New highs for vaccine stocks?
Investors in COVID-19 vaccine manufacturers have had little reason to rejoice in recent weeks. Top dogs Moderna and BioNTech have come back noticeably from their highs. Valneva's stock plummeted on Monday. Only newcomer Defence Therapeutics has held its ground at a high level. But for all of them, the calm could soon be over, and a new high could begin. Because people in other parts of the world are still not vaccinated. In addition, winter is just around the corner in Western countries, which means that Corona rates are rising. In addition, a new study shows the risk of long-COVID - such as memory and concentration deficits - even in children. With this mix, vaccine stocks face an exciting fall.
Read
Commented by Stefan Feulner on September 20th, 2021 | 12:05 CEST
Valneva, Cardiol Therapeutics, BioNTech - Recurring businesses
The vaccination rate is stalling. Around 4 million out of 24 million people over the age of 60 are still unvaccinated. Politicians led by Health Minister Jens Spahn have now launched a vaccination campaign week to get more people immunized against the coronavirus. The proportion of vaccinated people in Germany is still too low to prevent a new Corona wave and a possible resulting overload of the healthcare system. Meanwhile, vaccine producers are already working on the approval of booster shots. Profits should continue to bubble up for a long time.
Read
Commented by Fabian Lorenz on September 16th, 2021 | 11:34 CEST
Valneva, Barrick Gold, Central African Gold: Inflation fears and liberation strike
High inflation keeps investors on their toes. In August, the inflation rate in the US remained at a high level of 5.3% compared to the same month last year, as announced by the Labor Department of the world's largest economy. Therefore, the increase in consumer prices was only slightly below market expectations and the increase in July of 5.4%. Compared with the previous month, prices were 0.3% higher. Inflation data usually brings momentum to commodity stocks - positive as well as negative. This is as true for Barrick Gold as for Central African Gold, with one on a good path to higher prices. Valneva shareholders would like to see higher prices after the crash. However, analysts remain cautious.
Read